Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01634139
Recruitment Status : Completed
First Posted : July 6, 2012
Results First Posted : July 12, 2016
Last Update Posted : July 12, 2016
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Boehringer Ingelheim

Tracking Information
First Submitted Date  ICMJE July 3, 2012
First Posted Date  ICMJE July 6, 2012
Results First Submitted Date  ICMJE June 2, 2016
Results First Posted Date  ICMJE July 12, 2016
Last Update Posted Date July 12, 2016
Study Start Date  ICMJE July 2012
Actual Primary Completion Date June 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 2, 2016)
FEV1 Peak (0-3h) Change From Baseline [ Time Frame: Baseline and 24 Weeks. ]
Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 24. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
Original Primary Outcome Measures  ICMJE
 (submitted: July 3, 2012)
Peak forced expiratory volume in one second response within 3 hours post dosing (FEV1 peak0-3h response) [ Time Frame: after 24 weeks ]
Change History Complete list of historical versions of study NCT01634139 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 2, 2016)
  • Trough FEV1 Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from Baseline in Trough (pre-dose) Forced Expiratory Volume (FEV) in 1 second (FEV1) measured at week 24 and 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • FEV1 Peak (0-3h) at Week 48 Change From Baseline [ Time Frame: Baseline and Week 48. ]
    Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
  • FEV1 AUC (0-3h) Change From Baseline [ Time Frame: Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at week 24 ]
    Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
  • FEV1 Change From Baseline at Each Individual Timepoint [ Time Frame: Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks ]
    FEV1 change from baseline to week 24 at each individual timepoint. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • FVC Peak(0-3h) Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak(0-3h)) after 24 and 48 Weeks of treatment. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Trough FVC Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48 ]
    Change from baseline in Trough (pre-dose) FVC measured at week 24 and 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • FVC AUC (0-3h) Change From Baseline [ Time Frame: Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks ]
    Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants with available data at the timepoint of interest.
  • FVC Change From Baseline at Each Individual Timepoint [ Time Frame: Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at Week 24 ]
    FVC change from baseline to week 24 at each individual timepoint. The measured values presented are actually adjusted means The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Use of PRN (Pro re Nata) Rescue Medication Per Day [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used per day (24 hour period) based on the weekly mean at weeks 24 and 48. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Use of PRN Rescue Medication During Daytime [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during daytime based on the weekly mean at weeks 24 and 48. Measured values presented are actually adjusted means The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Use of PRN Rescue Medication During Nighttime [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during nighttime based on the weekly mean at weeks 24 and 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Peak Expiratory Flow (PEF) a.m. Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in the morning (a.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • PEF p.m. Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in the evening (p.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • PEF Variability Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in the peak expiratory flow variability based on the weekly mean at week 24 and 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • FEV1 a.m Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in morning (a.m.) FEV1 based on the weekly mean at week 24 and 48. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • FEV1 p.m. Change From Baseline [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in evening (p.m.) FEV1 based on the weekly mean at week 24 and 48. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • ACQ−IA Total Score [ Time Frame: Weeks 24 and 48. ]
    Interviewer Administered Asthma Control Questionnaire (ACQ-IA) total score after 24 and 48 weeks of treatment. The ACQ-IA is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ-IA total score is calculated as the mean of the responses to all 7 questions. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • ACQ−IA Responder Analysis [ Time Frame: Weeks 24 and 48 ]
    Responder categories based on the ACQ-IA total score after 24 and 48 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 <change from trial baseline <0.5) and worsening (change from trial baseline ≥0.5). No statistical testing was performed for ACQ-IA total score responders. The ACQ-IA is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.
  • PAQLQ(S) Total Score [ Time Frame: Weeks 24 and 48. ]
    Standardised Paediatric Asthma Quality of Life Questionnaire (PAQLQ(S)) total score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). Total Score is calculated as mean of all 23 questions. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • PAQLQ(S) Symptom Domain Score [ Time Frame: Weeks 24 and 48. ]
    PAQLQ(S) symptom domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score was calculated as the mean of the items in the domain. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • PAQLQ(S) Activity Limitation Domain Score [ Time Frame: Weeks 24 and 48. ]
    PAQLQ(S) activity limitation domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • PAQLQ(S) Emotional Function Domain Score [ Time Frame: Weeks 24 and 48. ]
    PAQLQ(S) emotional function domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain. The measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Responders in PAQLQ(S) at Weeks 24 and 48 [ Time Frame: Weeks 24 and 48. ]
    Responders in PAQLQ(S) at weeks 24 and 48. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≥0.5), no change (-0.5 <change from trial baseline <0.5) and worsening (change from trial baseline ≤-0.5). No statistical testing was performed for PAQLQ(S) total score responders. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control).
  • Change From Baseline in Nighttime Awakenings [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in nighttime awakenings based on the weekly mean at weeks 24 and 48. Nighttime awakenings was assessed by the question "Did you wake up during the night due to your asthma?" from the e-diary. Scores range from 1 (did not wake up) to 5 (was awake all night). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Change From Baseline in Morning Asthma Symptoms [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in morning asthma symptoms based on the weekly mean at weeks 24 and 48. Morning asthma symptoms was assessed by the question "how were your asthma symptoms this morning?" from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Change From Baseline in Daytime Asthma Symptoms [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in daytime asthma symptoms based on the weekly mean at weeks 24 and 48. Daytime asthma symptoms was assessed by the question "how were your asthma symptoms during the day?" from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Change From Baseline in Daytime Activity Limitations [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in daytime activity limitations based on the weekly mean at weeks 24 and 48. Daytime activity limitations was assessed by the question "how limited were you in your activities today because of your asthma?" from the e-diary. Scores range from 1 (not limited) to 5 (totally limited). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Change From Baseline in Daytime Experiences of Shortness of Breath [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in daytime experiences of shortness of breath based on the weekly mean at weeks 24 and 48. Daytime experiences of shortness of breath was assessed by the question "how much shortness of breath did you experience during the day" from the e-diary. Scores range from 1 (none) to 5 (a very great deal). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Change From Baseline in Daytime Experiences of Wheeze or Cough [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in daytime experiences of wheeze or cough based on the weekly mean at weeks 24 and 48. Daytime experiences of wheeze or cough was assessed by the question "did you experience wheeze or cough during the day?" from the e-diary. Scores range from 1 (not at all) to 5 (all the time). Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
  • Change From Baseline in Asthma Symptom-free Days [ Time Frame: Baseline and Week 24, Baseline and Week 48. ]
    Change from baseline in asthma symptom-free days based on the weekly mean at weeks 24 and 48. A day was considered as an asthma symptom-free day if there were no symptoms reported via the e-Diary (electronic diary) and no use of rescue medication reported via the eDiary during that day. Measured values presented are actually adjusted means. The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.
Original Secondary Outcome Measures  ICMJE
 (submitted: July 3, 2012)
  • Area under the curve from zero to 3 hours of the forced expiratory volume in one second (FEV1) response and area under the curve from zero to 3 hours ofthe forced vital capacity (FVC) response [ Time Frame: 24 weeks ]
  • Individual in-clinic forced expiratory volume in one second (FEV1) response and forced vital capacity (FVC) response response [ Time Frame: 24 week ]
  • Asthma control assessed by Asthma Control Questionnaire (ACQ-IA) [ Time Frame: 24 and 48 week ]
  • Number of responders assessed by Asthma Control Questionnaire (ACQ-IA) [ Time Frame: 24 and 48 week ]
  • Quality of life assessed by Paediatric Asthma Quality of Life Questionnaire (PAQLQ(S)) [ Time Frame: 24 and 48 week ]
  • Use of rescue medication [ Time Frame: 24 and 48 week ]
  • Change from baseline in mean weekly pre-dose morning and evening peak expiratory flow (PEF) measured by patients at home [ Time Frame: 24 and 48 week ]
  • Trough forced expiratory volume in one second (trough FEV1) response [ Time Frame: after 24 weeks ]
  • Trough forced expiratory volume in one second (trough FEV1) response [ Time Frame: after 48 weeks ]
  • Peak forced vital capacity response within 3 hours post dosing (FVC peak0-3h response) [ Time Frame: after 24 and 48 week ]
  • Trough forced vital capacity (trough FVC) response [ Time Frame: after 24 and 48 week ]
  • Change from baseline in mean weekly pre-dose morning and evening forced expiratory volume in one second (FEV1) measured by patients at home [ Time Frame: 24 and 48 week ]
  • Change from baseline in the absolute difference between morning and evening peak expiratory flow (PEF) value divided by the mean of these two values (weekly means will be compared) [ Time Frame: 24 and 48 week ]
  • Asthma symptoms assessed by the patient's electronic diary [ Time Frame: 24 and 48 week ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
Official Title  ICMJE A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma
Brief Summary The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children (6 to 11 years old) with moderate persistent asthma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Asthma
Intervention  ICMJE
  • Drug: Tiotropium low dose QD
    2 actuations once daily in the evening
  • Drug: Tiotropium high dose QD
    2 actuations once daily in the evening
  • Drug: Placebo
    2 actuations once daily in the evening
Study Arms  ICMJE
  • Experimental: Tiotropium high dose QD
    Intervention: Drug: Tiotropium high dose QD
  • Experimental: Tiotropium low dose QD
    Intervention: Drug: Tiotropium low dose QD
  • Experimental: Placebo QD
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 10, 2015)
403
Original Estimated Enrollment  ICMJE
 (submitted: July 3, 2012)
381
Actual Study Completion Date  ICMJE December 2015
Actual Primary Completion Date June 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

Inclusion criteria are:

  1. All patients' parent(s) (or legal guardian) must sign and date an informed consent prior to participation in the trial. In addition, an informed assent suitable for this age group has to be obtained from patients. A separate informed consent/assent is required for pharmacogenomic sampling.
  2. Male or female patients between 6 and 11 years of age.
  3. All patients must have at least a 6-month history of asthma.
  4. All patients must have been on maintenance treatment with an inhaled corticosteroid at a stable medium dose, either as mono treatment or in combination with another controller medication, for at least 4 weeks before Visit 1. While the LTRA is permitted throughout the trial, the LABA has to be stopped at least 24 hours prior to Visit 1, as no LABAs are permitted during screening and treatment period of this trial.
  5. All patients must be symptomatic (partly controlled) at Visit 1 and prior to randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ-IA) mean score >= 1.5.
  6. All patients must have a pre-bronchodilator forced expiratory volume in one second (FEV1) >= 60% and =< 90% of predicted normal at Visit 1.
  7. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator, considered as 100%) as compared to Visit 2 (pre-dose) must be within ± 30%.
  8. All patients must confirm the diagnosis of asthma by bronchodilator reversibility at Visit 1, resulting in an increase in FEV1 of >= 12%, 15 to 30 minutes after 200 mcg salbutamol/albuterol.
  9. Patients must be able to use the Respimat inhaler correctly.
  10. Patients must be able to perform all trial related procedures including technically acceptable pulmonary function tests and use of electronic diary/peak flow meter (diary compliance of at least 80% is required).

Exclusion criteria:

Exclusion criteria are:

  1. Patients with a significant disease other than asthma.
  2. Patients with a clinically relevant abnormal haematology or blood chemistry at screening.
  3. Patients with a history of congenital or acquired heart disease, or patients who have been hospitalized for cardiac syncope or failure during the past year.
  4. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year.
  5. Patients with a malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years.
  6. Patients with known active tuberculosis.
  7. Patients who have undergone thoracotomy with pulmonary resection.
  8. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the six weeks prior to Visit 1.
  9. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other components of the inhalation solution used with the Respimat inhaler.
  10. Pregnant or nursing female patients, including postmenarchal girl with a positive urine pregnancy test at Visit 1.
  11. Postmenarchal girl of child-bearing potential not using a highly effective method of birth control.
  12. Patients who have been treated with anti-IgE treatment within the last six months prior to Visit 1 and/or during the screening period.
  13. Patients who have been treated with systemic corticosteroids within four weeks prior to Visit 1.
  14. Patients who have been treated with systemic beta-adrenergics within four weeks prior to Visit 1.
  15. Patients who have been treated with oral beta-blocker medication within four weeks prior to Visit 1 and/or during the screening period.
  16. Patients who have been treated with inhaled long-acting anticholinergics or systemic anticholinergic treatment within four weeks prior to Visit 1 and/or during the screening period or who have been treated with inhaled short-acting anticholinergics within two weeks prior to Visit 1.
  17. Patients who have been treated with long-acting theophylline preparations within four weeks prior to Visit 1 and/or during the screening period or who have been treated with short-acting theophylline preparations within two weeks prior to Visit 1.
  18. Patients who have been treated with non-approved and according to international guidelines not recommended experimental drugs for routine asthma therapy within four weeks prior to Visit 1 and/or during the screening period.
  19. Patients who have taken an investigational drug within six half lives according to the investigator's information, or four weeks (whichever is greater) prior to Visit 1 and/or during the screening period.
  20. Patients who have previously been randomised in this trial or are currently participating in another trial.
  21. Patients with any acute asthma exacerbation or respiratory tract infection in the four weeks prior to Visit 1 and /or in four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.
  22. Patients requiring six or more puffs of rescue medication per day on more than two consecutive days in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks prior to Visit 2, the visit must be postponed.
  23. Patients who are unable to comply with medication restrictions prior to Visit 1 and or Visit 2.
  24. Patients with a known narrow-angle glaucoma, or any other disease where anticholinergic treatment is contraindicated.
  25. Patients with moderate to severe renal impairment, as defined by a creatinine clearance <50 mL/min/1.73 m2 BSA, as tiotropium is a predominantly renally excreted drug.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Years to 11 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Bulgaria,   Canada,   Germany,   Guatemala,   Hungary,   Korea, Republic of,   Latvia,   Lithuania,   Norway,   Portugal,   Romania,   Russian Federation,   Sweden,   Ukraine,   United Kingdom,   United States
Removed Location Countries Hong Kong,   Peru,   Taiwan
 
Administrative Information
NCT Number  ICMJE NCT01634139
Other Study ID Numbers  ICMJE 205.445
2011-001758-26 ( EudraCT Number: EudraCT )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Boehringer Ingelheim
Study Sponsor  ICMJE Boehringer Ingelheim
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
PRS Account Boehringer Ingelheim
Verification Date June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP